RxSight Light Adjustable Lens® Clinical Study​

Do you need cataract surgery? If so, you may be eligible to participate in a research study conducted by RxSight® to further evaluate an FDA-approved intraocular lens (IOL), the RxSight Light Adjustable Lens (LAL®). The LAL allows your doctor to adjust the power of the lens after it has been implanted in your eye to improve distance vision.

Approximately 500 men and women will participate in this study. During this study, patients will have a 66% (2/3) chance of receiving a Light Adjustable Lens™, and a 33% (1/3) chance of receiving a commercially available monofocal IOL. Patients will need to return to the doctor’s office for evaluation over a 6-month period.

You may qualify for this study if:

A formal consent process and eye exam are required before decisions can be made about your enrollment and willingness to be involved with this study.

Find Out If You Are a Candidate

Please fill out this form and our local study team will contact you shortly.

Clinical Study
Have you been diagnosed with cataracts?

Study Locations

To learn more about this study and whether you may be eligible to participate, you or your eye doctor may contact the nearest study research staff directly.


Vold Vision
2783 N Shiloh Dr
Fayetteville, AR 72704
Contact: Clinical Research Department
(479) 435-6440


Reeve Woods Eye Center
280 Cohasset Rd
Chico, CA 95926
Contact: Emma Chauvin
(530) 899-2244 x131


The Eye Institute of West Florida
1225 West Bay Dr
Largo, FL 33770
Contact: Renee C. Bondurant, BS, CCRC
(727) 581-8706

Newsom Eye
4211 US Hwy 27 N
Sebring, FL 33870
Contact: Xiomara Marcano
(863) 385-1544 x109


Vance Thompson Vision
2600 Jefferson St, Suite 200
Alexandria, MN 56378
Contact: Abby Garofalo
Miranda Danielson
(320) 391-9050


Vance Thompson Vision
4909 S 118th St
Omaha, NE 68137
Contact: Sara Hartnett, CCRC
(402) 506-9970


Center for Sight
330 S Rampart Blvd, Suite 360
Las Vegas, NV 89145
Contact: Clinical Research Manager
(702) 724-2005


Cleveland Eye Clinic
7001 S Edgerton Rd, Suite B
Brecksville, OH 44141
Contact: Erin Kus-Kreidler
(216) 503-6535

South Carolina

Carolina Eyecare Physicians
1101 Clarity Rd, Suite 100
Mt. Pleasant, SC 29464
Contact: Helga Sandoval, MD
(843) 380-2499

South Dakota

Vance Thompson Vision
3101 W 57th St
Sioux Falls, SD 57108
Contact: Elle Malmanger
(605) 371-7083


Focal Point Vision
343 W Sunset, Suite 1
San Antonio, TX 78209
Contact: Lisa Navarro
(210) 614-3600 x118

Key-Whitman Eye Center
11442 N Central Expressway
Dallas, TX 75235
Contact: Alex Bittermann
(214) 754-0000 x2295

Slade & Baker Vision
3900 Essex Lane, Suite 101
Houston, TX 77027
Contact: Johnelle Zarutskie
(713) 626-5544

Texas Eye Research Center
1852 Norwood Plaza Ct, Suite 101
Hurst, TX 76054
Contact: Barrett Bott
(817) 540-6060 x2060

LAL patients saw nearly as well without glasses (UCDVA) as control patients did with glasses (BCDVA).

The LAL provides optimized vision for patient satisfaction.2

LAL patients saw nearly as well without glasses (UCDVA) as control patients did with glasses (BCDVA).

Since the LAL is a monofocal lens, there is low risk of dysphotopsias caused by splitting light, leading to potentially enhanced vision and patient satisfaction.

LAL patients are approximately two times more likely to achieve 20/20 vision or better without glasses at 6 months.

The LAL offers LASIK-like accuracy in cataract surgery.2,3

92% of eyes (N = 391) achieved results within 0.50 D of target manifest refraction spherical equivalent (MRSE).

Patients are approximately two times more likely to achieve 20/20 vision or better without glasses at 6 months.

The study was a prospective, controlled, multicenter, 12-month study of 600 patients (ITT population) randomized to receive implantation with the RxSight LAL (N = 403) or a commercially available monofocal IOL (N = 197). Effectiveness analyses included 391 LAL patients and 193 control patients. Primary safety variables included best spectacle-corrected visual acuity (BSCVA) at 6 months and incidence of sight-threatening complications and adverse events. Primary effectiveness variables included percent reduction in manifest cylinder at 6 months, percent mean absolute reduction in MRSE at 6 months, and rotation of meridian of LAL at 6 months. Percent of eyes with an uncorrected visual acuity (UCVA) of 20/20 or better at six months post-operatively compared between the LAL treatment group and the monofocal control group was a secondary endpoint.

The Light Adjustable Lens corrects down to 0.5 diopters of postoperative cylinder.

The LAL corrects down to 0.5 diopters of astigmatism, which is the lowest level approved to be treated.

The ability to treat 0.50 D of postoperative cylinder makes the Light Adjustable Lens the only IOL in the United States approved to correct this level of vision-altering astigmatism. Astigmatism of as little as 0.50 D can reduce visual acuity by one line, and the impact on dynamic, functional visual acuity and low-contrast acuity is even greater.1